Tender detail
Conclusion of a non-exclusive discount agreement for the active substance Ublituximab
Summary
DAK-Gesundheit intends to conclude non-exclusive discount agreements with pharmaceutical companies for medicines containing the active substance Ublituximab (ATC L04AG14). The agreements will run from 1 December 2026 to 30 November 2028, or end earlier if an exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.